Document is current
Any future updates will be listed below
-
Authors
de Groot, Chiara C. https://orcid.org/0009-0005-1721-8596
Spruijtenburg, Bram https://orcid.org/0000-0002-6734-361X
Severin, Juliëtte A. https://orcid.org/0000-0002-5222-3017
van Dijk, Karin
Buil, Jochem B. https://orcid.org/0000-0003-4031-0778
Verweij, Paul E. https://orcid.org/0000-0002-8600-9860
de Jong, Auke W. https://orcid.org/0000-0002-0914-4612
Meijer, Eelco F. J. https://orcid.org/0000-0002-0226-024X
-
Funding
Funding for this research was provided by:
ZonMw (10150022310025)
- License Information
-
More Information
Article History
Received: 19 August 2025
Accepted: 5 November 2025
First Online: 10 January 2026
Declarations
:
: EFJM received research grants from Mundipharma and Scynexis, is on the scientific advisory board for Pfizer and has received speaker fees from Gilead Sciences. KD received a speaker’s fee and an advisory board fee from Pfizer and a speaker’s fee and an advisory board fee from Gilead. JBB received research grants from bioMérieux, advisory board fee from Shinogi and Gilead and speaker fees from Pfizer. All other authors declare no conflicts of interest.
: No ethical approval was required according to the Dutch Framework for the assessment of medical-scientific research not subject to the WMO by the Ministry of Health, Welfare and Sport. The COREON code of conduct for health research has been followed.
